| Name | Title | Contact Details |
|---|---|---|
Nicholas Ohler |
Chief Technology Officer | Profile |
THEON is a patient-focused drug discovery company developing small molecule correctors of RNA pathobiology.
Adarza BioSystems, Inc. manufactures a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.
NitroMed, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
Pathogen Detection Systems, Inc. is a Thunder Bay, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.